Recurrent ovarian cancer "" corresponds to the decitabine and reprogramming after cancer vaccines.

Chemotherapy and cancer vaccines administered prior to treatment with the drug decitabine is Journal of the American Association for cancer research, cancer immunology, Research Institute at Roswell Park cancer published was obtained for women with recurrent ovarian cancer is suggested to provide a treatment option for patients with this disease combination vaccine research Institute, this new clinical effects.

View the original article here

New Test May Help Predict Survival From Ovarian Cancer

Method was used to count special type of immune cells in tumors from 30 women in study

View the original article here

CA-125 change over time shows promise as screening tool for early detection of ovarian cancer

AppId is over the quota
AppId is over the quota

Evaluating its change over time, CA-125, the protein long-recognized for predicting ovarian cancer recurrence, now shows promise as a screening tool for early-stage disease, according to researchers at The University of Texas MD Anderson Cancer Center. The updated findings are published in Cancer; preliminary data were first presented at the 2010 American Society of Clinical Oncology (ASCO) annual meeting. If a larger study shows survival benefit, the simple blood test could offer a much-needed screening tool to detect ovarian cancer in its early stages – even in the most aggressive forms – in post-menopausal women at average risk for the disease.

Click here to read full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

View the original article here